USANA Health Sciences reported a net loss of $21.4 million for the second quarter ended July 4, 2026, driven by a $29.1 million preliminary non-cash goodwill impairment charge at its Hiya subsidiary and lower-than-expected performance from ventures Hiya and Rise Wellness. Consolidated net sales declined 5% year-over-year to $223 million, with Core Nutritional sales down 4% to $192 million while Hiya sales fell 17% to $28 million. The company updated its full-year fiscal 2026 outlook, lowering consolidated net sales guidance to $910 million and forecasting a net loss of $11 million compared to previous expectations of earnings between $20 million and $27 million. USANA operates in the health and wellness industry, developing and manufacturing nutritional supplements, functional foods, and personal care products sold through direct selling and retail channels.